ICP

PF3D7_0911900 (ICP, falstatin) is a chagasin-class (I42) cysteine protease inhibitor that regulates Plasmodium proteolysis across multiple stages of the parasite life cycle by selectively inhibiting parasite and host papain-family cysteine proteases (PMID:17083274, PMID:21742259). The recombinant P. falciparum protein is a potent, reversible, and selective inhibitor of the falcipain-2 and falcipain-3 cysteine proteases, while sparing falcipain-1 and dipeptidyl aminopeptidase 1 (PMID:17083274); inhibition is mediated by the BC loop, which contacts the target protease through hydrogen bonds, whereas the DE and FG loops are dispensable (PMID:24699522). A 2.6 Å crystal structure of the C-terminal inhibitory domain in complex with falcipain-2 establishes ICP as an I42 chagasin-like inhibitor and rationalizes its selectivity against cathepsin B-like proteases and the SERA5 protease-like domain (PMID:21742259), and the C-terminal domain alone is sufficient for inhibitory activity (PMID:20361051). Unusually, falstatin functions as a multimer, assembling into a thermostable decamer of five head-to-tail dimers whose oligomerization is driven by the C-terminal region and whose disordered N-terminus requires HSP70 for folding; it forms a 1:1 stoichiometric heterooligomer with ten subunits each of falcipain-2 and falstatin (PMID:24699522, PMID:38460641). ICP is expressed in a stage-specific manner during blood stages—present in schizonts, merozoites, and rings but absent in trophozoites—and is released on schizont rupture; antibody blockade of its inhibitory activity reduces erythrocyte invasion, implicating ICP in controlling proteolysis at the site of merozoite entry (PMID:17083274). Across rodent-malaria orthologs, ICP is essential and multifunctional: in P. yoelii and P. berghei it localizes to cytoplasmic vesicles, rhoptries, the parasitophorous vacuole, and exported exomembrane structures, and is released into host hepatocytes upon vacuole breakdown (PMID:23421981, PMID:20361051); genetic disruption in P. berghei abolishes sporozoite transmission through defective gliding motility, salivary-gland infectivity, and hepatocyte invasion (with enhanced circumsporozoite protein cleavage), all rescued by complementation, while blood-stage growth is attenuated (PMID:24281719, PMID:25166051). In addition to inhibiting parasite proteases such as yoelipain-2 (PMID:23421981), P. berghei ICP inhibits host cathepsin L-like cysteine proteases and, when expressed in mammalian cells, protects them from induced apoptosis (PMID:20361051).

1. 2006 High

   Establishing ICP's biochemical identity required showing whether it is a genuine, selective protease inhibitor; recombinant assays defined it as a potent, reversible, selective inhibitor of falcipain-2 and falcipain-3.

   Evidence In vitro enzymatic inhibition assays with E. coli-expressed recombinant protein across multiple parasite cysteine proteases

   PMID:17083274

   Open questions at the time

   • Molecular basis of selectivity not yet defined
   • In vivo substrates during the life cycle not established
2. 2006 High

   To connect biochemistry to parasite biology, its expression pattern and a functional role were tested; ICP is stage-specific (absent in the trophozoite stage of maximal protease activity) and its inhibitory activity is needed for efficient erythrocyte invasion.

   Evidence Stage-specific immunolocalization/fractionation and antibody-blockade erythrocyte invasion assays

   PMID:17083274

   Open questions at the time

   • Direct genetic evidence for the invasion role in P. falciparum absent
   • Which merozoite-surface proteolytic events ICP controls not identified
3. 2010 Medium

   Whether ICP acts beyond blood stages was unknown; work in P. berghei showed the ortholog is secreted by sporozoites, processed to liberate its C-terminal chagasin-like domain, released into host hepatocyte cytoplasm, and can block host apoptosis via cathepsin L-like protease inhibition.

   Evidence Immunofluorescence, fractionation, western blot for processing, in vitro inhibition of full-length and truncated protein, and induced-apoptosis assays in mammalian cells

   PMID:20361051

   Open questions at the time

   • Host protease target(s) mediating apoptosis protection not identified
   • Physiological relevance of apoptosis protection in vivo not established
   • Single-lab, single-method localization
4. 2011 High

   The structural basis of inhibition and family assignment were unresolved; the crystal structure of the C-terminal domain bound to falcipain-2 placed Plasmodium ICP in the I42 chagasin class and explained its target selectivity.

   Evidence 2.6 Å X-ray crystallography of the PbICP-C:falcipain-2 complex

   PMID:21742259

   Open questions at the time

   • Structure of full-length multimeric protein not resolved
   • Role of N-terminal region not addressed by the structure
5. 2013 Medium

   Direct genetic requirement and additional binding partners were unknown; refractoriness to deletion, exomembrane/vesicular localization, and interaction with yoelipain-2 established an essential blood-stage role and a new protease partner in P. yoelii.

   Evidence Targeted gene deletion attempts, live and marker co-localization imaging, and co-immunoprecipitation in P. yoelii

   PMID:23421981

   Open questions at the time

   • Essentiality inferred from deletion refractoriness rather than conditional knockout
   • yoelipain-2 interaction from single Co-IP without reciprocal validation
6. 2013 High

   Whether ICP has stage-specific functions in transmission was untested; clean genetic disruption in P. berghei showed it is required for sporozoite gliding motility and salivary-gland infectivity, correlating with excess circumsporozoite protein cleavage, without affecting blood-stage growth.

   Evidence Targeted gene disruption with gliding motility, salivary gland infection, and CSP cleavage assays in P. berghei

   PMID:24281719

   Open questions at the time

   • Protease responsible for CSP over-cleavage not identified
   • Mechanism linking protease inhibition to motility not resolved
7. 2014 High

   To confirm specificity and map the inhibitory determinant, conditional knockout/rescue and loop mutagenesis were performed; stage-specific knockout impaired hepatocyte invasion and liver-stage development (fully rescued by complementation), and the BC loop was identified as the inhibitory hot-spot, with falstatin found to act as a multimer.

   Evidence Conditional knockout with transgenic complementation and invasion/motility assays in P. berghei; site-directed BC/DE/FG loop mutagenesis with hemoglobin hydrolysis and peptide inhibition assays in P. falciparum/P. vivax

   PMID:24699522 PMID:25166051

   Open questions at the time

   • Functional consequence of multimerization for inhibition not defined at this stage
   • Blood-stage attenuation mechanism not resolved
8. 2024 Medium

   The oligomeric architecture and folding requirements were unclear; biophysical work showed the N-terminus is disordered and HSP70-dependent for folding, the protein forms a thermostable decamer of five head-to-tail dimers driven by the C-terminus, and binds falcipain-2 as a 1:1 ten-subunit heterooligomer.

   Evidence Protein-protein interaction assays, multiple biophysical techniques, computational modeling, and stoichiometric analysis in P. falciparum

   PMID:38460641

   Open questions at the time

   • In vivo role of HSP70-assisted folding not established
   • Functional significance of the decameric assembly for pathogen biology not demonstrated

• It remains unresolved which endogenous parasite and host proteases ICP controls at each life-cycle transition and how its multimeric assembly and stage-specific export are regulated to achieve stage-appropriate proteolytic control.
• Physiological substrate set per stage not defined
• Regulation of export and multimerization unknown
• Direct genetic proof of the erythrocyte-invasion role in P. falciparum absent